| アブストラクト | INTRODUCTION: Reports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established. RESEARCH DESIGN AND METHODS: The analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0. RESULTS: We searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008). CONCLUSION: Unlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data. |
|---|
| 投稿者 | McIntyre, Roger S; Mansur, Rodrigo B; Rosenblat, Joshua D; Rhee, Taeho Greg; Cao, Bing; Teopiz, Kayla M; Wong, Sabrina; Le, Gia Han; Ho, Roger; Kwan, Angela T H |
|---|
| 組織名 | Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada;;Department of Pharmacology and Toxicology, University of Toronto, Toronto,;Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario,;Canada. Electronic address: roger.mcintyre@bcdf.org.;Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.;Electronic address: rodrigo.mansur@uhn.ca.;Electronic address: joshua.rosenblat@uhn.ca.;Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department;of Public Health Sciences, Farmington, CT, USA. Electronic address:;taeho.rhee@yale.edu.;Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of;Education, Southwest University, Chongqing 400715, PR China. Electronic address:;bingcao@swu.edu.cn.;Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. Electronic;address: admin@bcdf.org.;Ontario, Canada. Electronic address: sabrinal.wong@mail.utoronto.ca.;Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto,;ON, Canada. Electronic address: hanny.le@mail.utoronto.ca.;Department of Psychological Medicine, Yong Loo Lin School of Medicine, National;University of Singapore; Institute for Health Innovation and Technology;(iHealthtech), National University of Singapore. Electronic address:;pcmrhcm@nus.edu.sg.;Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Faculty of;Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:;angela.kwan@mail.utoronto.ca. |
|---|
